Can continued lucerastat access help fabry patients?
NCT ID NCT07762638
First seen Aug 13, 2026 · Last updated Aug 14, 2026 · Updated 1 time
Summary
This program provides continued access to lucerastat for people with Fabry disease who were previously enrolled in a clinical trial of this drug. The goal is to allow these patients to keep receiving the treatment after the original study was stopped. It focuses on maintaining treatment continuity rather than testing new effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- lucerastat
- What this could lead to
- If successful, this program could help maintain treatment benefits for Fabry disease patients, potentially slowing disease progression.
- What could go wrong
- This is a post-trial access program, not a new efficacy study. It may not provide new evidence on long-term safety or effectiveness, and benefits are uncertain.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FABRY DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can early enzyme therapy save kidneys in fabry disease?
- Can a single gene infusion rewrite the story of fabry disease?
- Fabry disease sperm study halted early
- Heart study reveals hidden link between blood vessels and muscle blockage
- Taiwan study sheds light on rare fabry mutation and treatment effects
- Heart condition costs under the microscope in massive hospital study